ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
BlackRock, Inc. files an amended Schedule 13G reporting beneficial ownership of 8,274,763 shares of ASP Isotopes Inc. The amendment (Amendment No. 1) lists 8,274,763 shares beneficially owned, representing 6.6% of the class, with 8,117,277 shares of sole voting power and 8,274,763 shares of sole dispositive power. The cover shows a 03/31/2026 reference and the filing is signed on 04/27/2026. The filing states the holdings reflect aggregated positions of Reporting Business Units of BlackRock and notes various persons may have rights to dividends or proceeds but no other single person holds more than 5%.
ASP Isotopes Inc. COO Robert Ainscow reported an open-market sale of 22,500 shares of Common Stock at a weighted average price of $5.205 per share. According to the disclosure, this was a "sell to cover" transaction under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, he directly held 1,490,317 shares, so the transaction represents a small portion of his overall position.
ASP Isotopes Inc. Chief Financial Officer Heather Kiessling reported an open-market sale of 23,124 shares of common stock on April 15, 2026 at a weighted average price of $5.478 per share. The footnotes state this was a "sell to cover" under a Rule 10b5-1 trading plan adopted on December 19, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, she directly holds 709,376 shares of ASP Isotopes common stock.
ASP Isotopes Inc. director Duncan Moore reported multiple stock transactions. He sold 11,642 shares of common stock at a weighted average price of $5.205 per share in an open-market trade. Following this sale, he directly owned 1,044,928 shares of ASP Isotopes common stock.
The filing also shows two earlier awards of restricted stock for his service as an independent director: 25,469 shares on November 12, 2025 and 36,548 shares on December 18, 2025, both granted at no cash cost. The sale on April 16, 2026 was executed under a Rule 10b5-1 trading plan adopted on December 31, 2025 and included shares sold to cover income tax liabilities from the vesting of a prior restricted stock award.
ASPI submitted a Form 144 notice regarding the potential sale of 25,469 shares of Common Stock. The shares were acquired as compensation (Restricted Stock Award) on 11/12/2025. The filing is dated 04/16/2026 and lists NASDAQ trading.
ASP Isotopes Inc. reported proposed and recent sales of Common Stock by an affiliate via a Form 144 disclosure. The filing shows a 400,000-share Restricted Stock Award acquired 04/14/2025 and two recent dispositions: 8,438 shares sold on 03/06/2026 for $45,894.28 and 25,000 shares sold on 04/13/2026 for $112,775.00.
The record lists these trades as equity compensation and brokered sales; the filing names Robert Ainscow as the selling contact. Timing and amounts are shown explicitly in the disclosure.
ASPI filed a Form 144 notice reporting proposed sales of Common Stock. The excerpt lists quantities including 231,240 and 23,124 tied to restricted stock awards and a larger figure 125,903,447 in the securities information row with date 04/15/2026.
ASP Isotopes Inc. COO Robert Ainscow reported an open‑market sale of 25,000 shares of common stock on March 6, 2026. The sale was executed at a weighted average price of $4.511 per share, with individual trades ranging from $4.42 to $4.58.
These sales were made under a pre‑arranged Rule 10b5-1 trading plan adopted on December 13, 2024, indicating they were scheduled in advance. Following this transaction, Ainscow directly holds 1,512,817 shares of ASP Isotopes common stock.
ASPI notice of proposed sale under Rule 144. A reporting person indicated a proposed sale of 300,000 shares of Common Stock that were acquired as a Restricted Stock Award on 09/06/2024. The filing also shows 8,438 shares sold in the past three months for $45,894.28. Shares outstanding are listed as 125,903,447 as of 04/13/2026.
ASP Isotopes Inc. provided a broad business and financial update, pairing strong balance sheet growth with long‑term profitability goals. The company reported cash, cash equivalents and marketable securities of $333 million as of December 31, 2025, after raising over $345 million in 2025 through common stock and convertible notes. Product revenue for 2025 was $5.7 million, up 46% from $3.9 million in 2024, while net loss attributable to shareholders widened to $175.1 million from $32.3 million.
Management outlined a long‑term EBITDA target of more than $300 million in 2031 and expects first commercial isotope shipments in 2026 across Silicon‑28, Carbon‑14 and Ytterbium‑176. The Virginia Gas Project’s Phase 1 drilling finished roughly four months early, with nameplate capacity of 2,500 GJ per day of LNG and 58 MCF per day of liquid helium expected in the third quarter of 2026.